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Adriene Whitaker, MPH 
University of Pittsburgh, 2007
 
 
Amyotrophic lateral sclerosis (ALS), an incurable neuromuscular disease, causes progressive 
paralysis resulting in respiratory failure and ultimately death. Although there are only 30,000 
people nationwide living with ALS, this population is of significant public health concern as 
those afflicted with ALS suffer from progressive symptoms of disability, making them a 
particularly vulnerable population in need of public health advocacy for improved access to 
medications and care.  As the symptoms of disability become increasing acute in the final 
months of life, achieving the best quality of life possible is of paramount importance. To achieve 
this, a number of medications exist to both treat the direct and indirect symptoms of ALS. 
The purpose of this thesis is to examine barriers terminal ALS patients experience in 
accessing medications, medication trends as ALS patients near death, and the effect of 
medications on quality of life for ALS patients in the terminal phase of the disease. Literature 
pertaining to the terminal phase of ALS was reviewed and an analysis of secondary data was 
performed. The data analyzed for this thesis was from the National Institute of Mental Health 
grant funded Living with ALS study, which collected medication data in the preceding months 
before death from terminal ALS patients. For the purposes of this analysis, patient medications 
were categorized into four domains: ALS treatment medications, palliative medications, mood 
medications, and other medications. The correlation between the medication domains and 
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sociodemographic and quality of life indicators were investigated. Changes in medications over 
time were also investigated. 
Results of the analysis revealed that those with higher incomes and educational 
attainment were taking significantly fewer palliative medications. Additionally, those on 
Medicaid were on significantly fewer other medications. Finally, across all medication domains, 
medication use declined significantly as patients approached imminent death. These findings 
suggest that the medications used to treat the symptoms of ALS do little to improve symptoms 
and even less to improve quality of life. Future research recommendations include exploring 
patients’ motivations for discontinuing medications, improving symptom management 
medications, and improving ALS patients’ access to both pharmacological and non-
pharmacological interventions to improve overall quality of life. 
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1.0  INTRODUCTION 
Amyotrophic lateral sclerosis (ALS) is a neuromuscular disease that causes progressive paralysis 
resulting in respiratory failure and ultimately death. The central focus of care for this fatal and 
incurable disease is improved quality-of-life, which is achieved through pharmacological and 
non-pharmacological interventions. The purpose of this thesis is to examine barriers terminal 
ALS patients experience in accessing medications, medication trends as ALS patients near death, 
and the effect of medications on quality of life for ALS patients in the terminal phase of the 
disease. If patient comfort and improved quality of life are the essential priorities of ALS care, 
what medications do patients continue, stop or initiate as they are faced with progressive disease 
in the last six months of life? To answer this question, this thesis will examine literature 
pertaining to the terminal phase of ALS and report the findings of a secondary data analysis. The 
data to be analyzed for this thesis is from the National Institute of Mental Health grant-funded, 
Living with ALS study. The Living with ALS study was performed at the Eleanor and Lou 
Gehrig MDA/ALS Research Center at Columbia University and other surrounding clinics in 
New York from January 2000 to June 2004. 
Although ALS affects only 30,000 people nationwide, this population is of significant 
public health concern. Those afflicted with ALS suffer from progressive symptoms of disability, 
making them a particularly vulnerable population, quite literally without a voice of their own. 
Pubic health professionals are charged not only with protecting the health of the public at large 
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but are also charged with assuring that our most vulnerable populations receive the healthcare 
services they need. ALS patients and their families are a population in need of public health 
advocacy for improved end-of-life care. By investigating terminal ALS patients’ access to 
medications, insights on how to improve barriers to access of care can be identified and better 
end-of-life care achieved. 
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2.0  BACKGROUND 
2.1.1 Amyotrophic Lateral Sclerosis (ALS) 
Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease, is the most common 
motor neuron disease. This fatal, incurable, neurodegenerative disorder is characterized by the 
death of motor neurons in the brain and spinal cord, causing symptoms of progressive paralysis 
of skeletal muscles, muscle atrophy, and hyperreflexia.1 The initiating factor that causes neuron 
death is not fully understood. It is believed however, that altered mitochondrial function,2 
oxidative damage,3and a glutamate reuptake malfunction4 may all contribute to the demise of the 
neuron. As the disease progresses, patients experience increased muscle weakness across all 
body regions, leading to the inability to walk, feed and toilet themselves, speak, and swallow. 
Eventual death is most commonly caused by respiratory failure due to thoracic and upper 
cervical spine involvement.5 
Worldwide the incidence rate of ALS is 0.86 to 2.4 per 100,000 with an elevated 
incidence of ALS among men. The onset of symptoms usually occurs in mid to later life with a 
peak age of onset at 65-74 years of age.6 Murray,7 in a review of more than 20 studies, found the 
duration of disease, from symptom onset to death, ranged from a mean of 26.6 months to a mean 
of 47 months with a median survival of approximately three years.    
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2.1.2 Direct and Indirect Symptoms of ALS 
As ALS progresses, patients are faced with numerous symptoms that are indirectly and directly 
caused by ALS. Symptoms directly caused by ALS include weakness and muscle atrophy, 
fasciculations and muscle cramps, spasticity, dysarthria (the inability to communicate), 
dysphagia (difficulty swallowing), sialorrhea (excessive salivation or drooling), dyspnea 
(shortness of breath), and involuntary emotional expression disorder. Indirect symptoms include 
anxiety, depression, sleep disturbances and insomnia, constipation, and musculoskeletal pain. 1 
2.1.3 The Terminal Phase of ALS 
ALS, although considered a fatal condition, is unlike many other incurable illnesses in that the 
progression of disease may take years before death occurs. Even as the ALS patient exhibits 
signs and symptoms of progressive debilitation, it is often difficult to predict life expectancy.8 As 
patients near the terminal phase of the disease nutritional impairment and respiratory difficulties 
become more acute. To determine the terminal phase of the disease (a life expectancy of six 
months or less) a number of predictive factors exist. Medicare deems an ALS patient to have a 
life expectancy of six months or less if he/she meets one of the following criteria: (1) Patient 
must demonstrate critically impaired breathing (a forced vital capacity (FVC) of less than 30%, 
significant dyspnea at rest, oxygen needed at rest, and patient refusal of invasive ventilation); (2) 
Patient must demonstrate both rapid progression of ALS and crucial nutritional impairment; or 
(3) Patient must demonstrate both rapid progression of ALS and life-threatening complications. 9 
In contrast Del Bene et al.,10 determined that a revised set of criteria would provide a 
more accurate measure in predicting a six-month survival. In their revised criteria, patients with a 
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FVC of 30% without other inclusive criteria would be considered to be in the terminal phase of 
the disease. In addition those patients with a FVC of less than 60% with steady decline of the 
FVC over the preceding two-three months and who also manifested at least two other respiratory 
indicators, or one respiratory and one nutritional indicator, were also deemed to be in the 
terminal phase of the disease.  
Accurate guidelines for the terminal phase of ALS are imperative in providing 
appropriate end-of-life care. Hospice, which is most often covered by Medicare and other 
privates insurances, aims to provide improved quality of life and quality of death through 
assessment, symptom management, spiritual and psychological counseling, and improved access 
to services, medical equipment, and medications. To be eligible for these hospice services, the 
patient’s life expectancy must be six months or less. As such, end-of-life indicators must 
accurately reflect the course of the disease for hospice to be beneficial for the dying ALS patient. 
Numerous researchers in the field have advocated the revised Del Bene et al. end-of-life hospice 
measures. An ALS Peer Workgroup that was charged with investigating end-of-life care 
reported:  
Medicare and other insurers lack correct information regarding markers for end of life in 
ALS. Current hospice referral guidelines are not relevant to ALS, and hospice intake 
forms do not ask questions that accurately reflect the patient’s condition. Medicare 
Criteria for admission to hospice are too restrictive for ALS patients, thus patients with 
ALS are referred to hospice too late to benefit from the supportive services that hospice 
offers.11 
2.2 PHARMACOLOGICAL TREATMENT AND SYMPTOM MANAGEMENT 
From diagnosis through the terminal phase of ALS, maximizing quality of life is the central 
focus of care. In order to maintain and when possible improve quality of life, a number of 
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pharmacological interventions are available to assist in the treatment of symptoms. Although no 
curative treatment exists, the glutamate antagonist riluzole12 has been approved by the FDA for 
prolonging the life of ALS patients. In a 2007 review the Cochrane Collaboration concluded:  
Riluzole 100mg daily probably prolongs median survival by two to three months in 
patients with probable and definite amyotrophic lateral sclerosis with symptoms less than 
five years, forced vital capacity greater than 60%, and age less than 75 years. 13 
 
Unfortunately riluzole, the only FDA approved medication to treat ALS, minimally extends life, 
and research has yet to determine if there is any effect on quality of life or functionality.  In an 
effort to treat ALS and prolong life, there are a number of additional medications frequently 
taken by ALS patients.  Although many of these medications have been in clinical trial, none is 
FDA approved for the treatment of ALS. These medications include creatine,14 a supplement to 
assist in mitochondrial function, antioxidants,15 to aid in the repair of oxidative damage, and 
gabapentin,16 a glutamate-blocking agent. 
Moreover, a number of other pharmacological interventions exist to ease symptoms 
directly and indirectly associated with ALS and provide increased comfort for the ALS patient. 
Antidepressants, anxiolytics, analgesics, skeletal muscle relaxants, anticholinergics, laxatives, 
and sedatives are all commonly used to treat disease-specific symptoms.  
2.2.1 Medication Trends: The ALS CARE Database 
As ALS progresses, the treatment regimen prescribed by clinicians has been shown to vary 
greatly depending on the continent, country, and even city where the patient receives care.17 Due 
to the lack of randomized control trials directly investigating symptom management and 
available evidence-based standards, the management of ALS symptoms has largely relied on 
clinician experience and anecdotal reports from patients and experts within the field.18, 19 
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In an effort to provide an optimal standard of care for patients with ALS, the ALS Patient 
CARE Database was established in 1996.20 The ALS CARE Database aims to identify ALS 
treatment trends, establish research needs, and provide insight for improved practice by 
collecting data from patients, caregivers and neurologists. All neurologists across North 
America, regardless of practice setting, are invited to provide patient data. Data are collected and 
entered by the neurology practice at the patient’s baseline visit and at subsequent visits at 6, 12, 
18, and 24 months.18 With more than 5600 ALS patients enrolled across North America, the ALS 
CARE Database has been able to capture significant data, especially pertaining to disease-
specific medication trends. The proportion of patients taking common ALS medications such as 
riluzole, creatine, gabapentin, high dose vitamins, antioxidants, and other non-traditional 
medications are summarized in Table 1. Additionally, Table 1 summarizes the proportion of 
enrolled ALS patients medicated for the treatment of sialorrhea, depression, emotional lability, 
and pain. Content included in Table 1 is based on the Miller et al.18 findings. 
Table 1: Results from the ALS Care Database: Pharmacological Interventions 
Medication % of patients† 
riluzole 52% 
creatine 39% 
gabapentin 14% 
high dose vitamins or antioxidants 48% 
non-traditional 15% 
 
Symptom % of patients medicated for symptom 
sialorrhea 25%†† 
depression 34%††† 
emotional lability 44%†††† 
pain (terminal phase) 80%† 
†Source did not indicate whether the percentage of patients was an average over the total 
number of years the ALS CARE Database has been in existence or if the percentage was an 
average for a particular year. 
†† The number of patients taking medications for sialorrhea ranged from a low of 12% in 1999 
to high of 25% in 2002. 
†††Percentage of patients treated with antidepressants in 2003. 
†††† Percentage of patients treated for emotional lability ranged from a low of 29% in the period 
prior to 1999 to a high of 44% in the period following 1999. 
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 Furthermore, the ALS CARE Database found that pharmacological interventions used for 
the treatment of depression, constipation, spasticity, cramps, insomnia, and sialorrhea were 
generally reported by patients to be effective. Unfortunately, the large majority of patients were 
not on any symptomatic therapies. 
Although the ALS CARE Database has undoubtedly made a significant impact on how 
clinicians practice, it does have a number of limitations. One significant limitation is that 
disease-specific medications are reported by the physician rather than the caregiver or patient, 
who may be more appropriate to report what medications the patient is actually taking. Another 
significant challenge, particularly pertaining to gathering end-of-life data, is obtaining continued 
follow-up data from patients. Patient data are to be collected and entered at baseline, 6, 12, 18 
and 24 months. However, the number of patients with data at each of these milestones drops 
rapidly from 1838 to 1334, 736 and 682 respectively.18 Patient death certainly accounts for some 
of the missing data, but the number of patients lost to follow-up is another significant factor to 
consider.   
2.3 THE TERMINAL PHASE OF ALS: AVAILABLE RESEARCH AND 
RECOMMENDATIONS FOR CARE 
2.3.1 Available Research 
Although the ALS CARE Database has been able to provide significant insight into medication 
trends and population-based data, little has been published about ALS-specific pharmacological 
 8 
interventions in the terminal phase of the disease. In an effort to gain insights about the terminal 
phase, Mandler et al.21 used data from the ALS CARE Database to explore whether or not ALS 
patients experience a “good death.” The ALS CARE Database collected end-of-life data on 1014 
ALS patients and found that 90.8% were considered to have died “peacefully.” A peaceful death 
was defined as “occurring under the least amount of distress and often related to progressive 
carbon dioxide narcosis, with little pain or dyspnea, as witnessed and reported by the relative or 
caregiver present during the end-of-life period.” Interestingly, results of the CARE database also 
revealed that low income and not dying at home correlated with the experience of not dying 
peacefully.  
While results of the ALS CARE Database indicate that most ALS patients have a 
peaceful death, conflicting reports exist. In a study performed by Ganzini et al.,22 the 
investigators explored the final month of life of ALS patients and discovered that one-third of 
caregivers were dissatisfied with some aspect of symptom management. In the last month of life, 
56% of patients experienced dyspnea either frequently, almost all the time, or constantly and 
48% experienced discomfort other than pain either frequently, almost all the time, or constantly. 
With such a high caregiver dissatisfaction and severe discomfort and dyspnea among patients, it 
appears that ALS patients in the terminal phase of the disease could benefit from more 
aggressive treatment of symptoms. 
Moreover, it has been argued that ALS patients who desire physician-assisted suicide or 
who would consider hastening their death also lack effective and appropriate end-of-life care. In 
a study by Albert et al.,23 43.4% of terminal phase ALS patients thought about ending their life, 
18.9% expressed a desire to die, and 5.7% took actions to hasten their deaths. In a similar study 
by Ganzini et al.,24 56% of ALS patients indicated that they would consider assisted suicide and 
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of those who consider assisted suicide, 78% would request a lethal prescription from a physician 
if it were legal. In response to these studies, Carter et al.25 reported: “…the stunningly high 
percentage of ALS patients who would consider [ending their lives] strongly implies that the 
quality of care in advanced ALS is inadequate.” 
2.3.2 Recommendations from the AAN Practice Parameters 
In 1999 the Quality Standards Subcommittee (QSS) of the American Academy of Neurology 
(AAN) published practice parameters for the care of ALS patients.26 The practice parameters set 
forth by the AAN were based on an extensive review of evidence-based research and strived to 
provide best practice standards for the management of ALS and identify areas in which further 
research is needed. The AAN reported:  
The practice parameters presented here comprise the first recommendations for the 
management of ALS based on a prescribed review and analysis of the peer-reviewed 
literature. These practice parameters were developed to improve the care and the quality 
of life of people with ALS by providing a rational basis for managing the disease. 26 
 
Since their publication in 1999, the practice parameters have led to significant changes in how 
clinicians manage the progression of ALS, and as a result there has been an increase in the 
number of both pharmacological and non-pharmacological interventions prescribed for 
patients.27 
The task force charged with developing the practice parameters investigated five areas of 
care, one of which was “advanced directives and palliative care.” The AAN reported: “As ALS 
progresses, the goal of patient care changes from maximizing function to providing effective and 
compassionate palliative care.” In a collaborative review of evidence-based literature, the 
following four questions were investigated: 
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• Is pain common in the terminal phase of ALS? 
• Can terminal dyspnea be relieved by therapeutic intervention? 
• Does hospice care improve quality of life in the terminal phase? 
• Do advance directives improve quality of life in the terminal phase of ALS? 
After a review of the literature, the AAN reported 40-73% of ALS patients experience 
pain in the later stages. Immobility was described as the most likely source of discomfort, 
causing pressure on the skin and joints as well as muscle cramping and stiff joints. The AAN 
recommended the use of non-narcotic analgesics, anti-inflammatory drugs, and antispasticity 
agents for initial treatment of pain. In patients who are unresponsive to these, the liberal use of 
opioids is recommended following the World Health Organization’s guidelines for pain 
management for cancer patients. 
Two of the most common and unpleasant symptoms of the terminal phase of ALS are 
dyspnea and anxiety. The AAN reported approximately 50% of patients with ALS experience 
dyspnea from respiratory muscle weakness, and anxiety caused by dyspnea is a common 
symptom among ALS patients suffering from respiratory insufficiency. Dyspnea relief, however, 
was rated as “good” by 81% of hospice patients with ALS when opioids were used. The AAN set 
forth recommendations that included the use of short-acting anxiolytics for anxiety and the use of 
opioids and supplementary oxygen as needed. 
The role of hospice was also explored by the AAN. While a number of studies have been 
conducted on the use of hospice care, consensus has not been reached as to its effectiveness. 
Uncontrolled studies have shown that hospice care provides improved pain management and 
peaceful deaths. The AAN recommends that clinicians consider hospice referrals in the terminal 
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phase of ALS but also emphasize that there continue to be research gaps as to the effect of 
hospice care on quality of life and inpatient versus homecare hospice services.  
Finally, the AAN found no evidence that advance directives improve quality of life for 
any disease. Moreover, the evidence the AAN reviewed showed that advance directives did not 
substantially enhance physician-patient communication or aid in patient healthcare decision-
making among seriously ill cancer patients. Despite this, the AAN still recommends their use. 
Studies have shown that physicians and patients would like to utilize directives more effectively. 
The AAN suggests this can be done by initiating discussion of advance directives early in the 
course of the disease and by creating therapy-specific treatment guidelines rather than broad 
generalities. As ALS progresses, often this population’s preference for care can change. Thus, 
the AAN recommends updating advance directives every six months to accurately reflect patient 
desires.  
2.3.3 Recommendations from an ALS Peer Workgroup 
Promoting Excellence in End-of-Life Care is a national program sponsored by the Robert Wood 
Johnson (RWJ) Foundation. The RWJ Foundation aims to improve care of the dying and has 
recognized ALS patients as a special population in need. In an effort to address end-of-life care, 
an ALS Peer Workgroup was established to work collaboratively with the ALS Association. The 
Workgroup was convened to explore current palliative practice during the terminal phase of ALS 
and make recommendations for improvement. The findings of this ALS Peer Workgroup were 
published in 2005.11 
The ALS Workgroup confirmed that there are very few studies that specifically 
investigate and identify optimal treatment of the dying ALS patient. The Workgroup also 
 12 
acknowledged that due to the lack of evidence-based research on the terminal ALS patient, the 
Practice Parameters set for by the AAN for palliative care have been largely influenced by 
cancer research. Due to lack of evidence, the Workgroup’s major contribution has been 
identifying the gaps in research and making recommendations for improved prospective studies.  
Moreover, the Workgroup recognized that beyond symptom management and 
psychological care, ALS patients face considerable barriers to both accessing care and securing 
the financial means necessary for the cost of care. The Workgroup set forth a number of policy 
recommendations for the improved care of the dying ALS patient. These recommendations 
included developing a comprehensive reimbursement program to cover the cost of 
hospitalizations, medications, physical therapy, assistive devices, and homecare. In addition, they 
strongly supported the revision of hospice and Medicare guidelines to more accurately reflect 
end-of-life indicators to better benefit the patient. 
2.3.4 Implications for Future Research 
As evidenced by the findings of the AAN Practice Parameters and the RWJ Foundation ALS 
Peer Workgroup, very few studies exist that specifically investigate and identify best practice 
standards based on findings about terminal ALS patients. Although the ALS CARE Database 
and AAN Practice Parameters have made significant strides in providing evidence-based care as 
ALS progresses, much research is still needed to refine standards of care for the terminal phase 
of this disease.   
Additionally, to date there have been no published data on medication trends in the 
terminal phase of the disease, nor has there been any research on medication trends in which the 
patients and/or their caregivers reported medication use. Patient and/or Caregiver reported 
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medications could potentially reflect more accurately what the ALS patient takes on a day-to-day 
basis. Furthermore, although efficacy of individual medications has been determined, no research 
has been completed on terminal ALS patients’ medication choices. Although clinicians can 
suggest best practice standards to their patients, individual choice and patients’ rights to refuse 
medications should be considered. For an array of reasons including unpleasant side effects, cost, 
and no demonstrated personal benefits, patients and physicians may not comply with the 
recommendations set forth by the AAN practice parameters. More research is needed to identify 
what medication choices terminal patients make so that improved interventions for both quality 
of life and quality of death can be developed. 
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3.0  PURPOSE, RESEARCH QUESTIONS, AND HYPOTHESES 
3.1.1 Purpose 
As identified by the literature, a major knowledge gap exists as to what medications terminal 
ALS patients take over the last six months of life. In an effort to gain further insight about 
medications use in the terminal phase of ALS, this thesis will analyze secondary data from the 
National Institute of Mental Health grant-funded study performed at the Eleanor and Lou Gehrig 
MDA/ALS Research Center at Columbia University and other surrounding clinics in New York 
from January 2000 to June 2004. This Living with ALS study collected data on disease 
management and mental health indicators from terminal ALS patients and their caregivers. 
Included in this secondary data are the medications the terminal ALS patients took while 
enrolled in the study, as reported by their caregiver. 
The purpose of this analysis is to identify what medications terminal ALS patients take in 
the last six months of life, what trends emerge, how hospice services and economic and 
educational status of the patient and caregiver affect access to medications, and how medications 
affect quality of life.  
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3.1.2 Research Questions 
The specific research questions investigated in this thesis include: 
1. What medications are ALS patients taking during the last six months of life? 
2. What changes in medications occur over the last six months of life? 
3. Is there a relationship between economic and educational status of the patient/caregiver 
and medications taken? 
4. Does the utilization of hospice services increase the number of palliative medications 
taken by a participant? 
5. What relationship exists between medications taken by patients and quality of life? 
3.1.3 Hypotheses 
1. I anticipate the medications taken by patients in the Living with ALS study will mimic the 
results already obtained by the ALS CARE Database, as there is little evidence and few practice 
parameters to guide physicians in the terminal phase of ALS. I expect that care in the last six 
months does not dramatically change until death is imminent. Only a minority of patients in the 
Living with ALS study will have prescriptions for palliative medications, ALS treatment 
medications, or mood medications. 
2. As patients near death, I expect the number of chronic medications and ALS treatment 
medications taken by patients will significantly decline.  However, I also expect that as the 
patient approaches imminent death the number of palliative and mood medications will increase.  
3. I anticipate disparities in access to medications; namely, that those with higher education 
status and increased monetary means will be on more medications, as they may be more likely to 
seek out additional treatments.  
4. I predict that the utilization of hospice services will increase the number of palliative and 
mood medications. Typically, having hospice services increases the number of symptom 
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assessments by clinicians and nurses, which may increase the number of palliative medications 
they prescribe. Additionally, hospice services that are covered by Medicare or other private 
insurances provide substantial financial assistance to cover medication costs that are disease-
specific. 
5. I anticipate an increased quality of life with the use of palliative medications and mood 
medications. Medications available to patients are completely palliative and are given in hopes of 
increasing quality of life. As such, those patients taking palliative or mood medications should 
have increased quality of life indicators.  
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4.0  STUDY DESIGN OF THE SECONDARY DATA SOURCE 
The secondary data source, the Living with ALS study, explored the ways in which ALS affects 
patients and their families. Specifically, this study aimed to gain insights from patients and their 
primary caregiver about how they managed ALS, how ALS has affected their mood, what 
services patients utilize, and what plans patients made as they lived with ALS. Approval for this 
study was obtained through the Institutional Review Boards of Columbia-Presbyterian Medical 
Center and the New York State Psychiatric Institute. Described below are the eligibility criteria 
for patients and their caregivers, the procedure for collecting data, and the measures used in this 
study. 
4.1.1 Participant Eligibility 
Interviews were conducted with ALS patients who demonstrated advanced disease and who had 
a life expectancy of approximately six months. The indicator used to predict life expectancy was 
a forced vital capacity of <50%.  As previously discussed in this thesis, this value has been 
related to anticipated death within six months.10 Eligible patients had to be English speaking, 
able to communicate “yes” or “no” responses, have a non-paid caregiver who agreed to 
participate in the interviews, and live within a three-hour drive of the medical center conducting 
the research. Individuals were excluded from the study if they met criteria for dementia or were 
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on mechanical ventilation at the time of enrollment. Approximately 94% of participants were 
enrolled from the Eleanor and Lou Gehrig MDA/ALS Research Center at Columbia University. 
An additional 6% of participants were enrolled through various other clinics and hospices in the 
area.  
4.1.2 Procedure 
Clinicians at both the ALS center and other clinics identified potential participants based on the 
inclusion and exclusion criteria stated above. The purpose and procedure of the study were 
explained by the clinician, and if patients and caregivers expressed an interest in participating, 
clinicians obtained consent to forward their contact information to the principal investigator. The 
principal investigator then called the potential participants to provide a more in-depth 
explanation of the study, to review the consent form, and to answer any additional questions. 
Once a verbal consent had been obtained, trained interviewers scheduled visits at a time and 
place that would be convenient for the patient and caregiver. The majority of interviews were 
conducted in the homes of the participants.  
On the first interview, the research team obtained written consent and administered the 
first interview. Patients and caregivers were interviewed separately. Follow-up interviews were 
conducted monthly until the patient met a study endpoint of either tracheostomy or death. For 
those patients who chose to have a tracheostomy, the interview schedule was changed to every 
three months following tracheostomy. One additional interview was conducted with the 
caregiver after the death of the patient.  
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4.1.3 Measures 
Because the patients in this study demonstrated advanced disease with a high likelihood of death 
within six months, a variety of information was requested of the caregiver rather than the patient. 
Information about demographics for the patient and caregiver, patient medications, and services 
utilized were included in the caregiver interviews only. In addition, caregivers were asked a 
series of four questions to establish the patient's overall status. These questions assessed 
concentration, memory, emotional lability and ability to follow a plot when reading or watching 
TV.  
To measure the progression of the disease, the patient and caregiver were asked to 
complete the ALS Functional Rating Scale (ALSFRS).28 The ALSFRS is a validated instrument 
used to measure the progression of disability. The four domains of the questionnaire include 
gross motor skills, fine motor skills, bulbar function, and respiratory status. Each of the 12 items 
of the questionnaire was rated on a four-point scale. When the sum of the tallied scores is 
calculated, those with lower scores have a greater amount of disability and have increased 
difficulty with swallowing and breathing. 
Depression was assessed using the Beck Depression Inventory-Revised (BDI-II).29 The 
BDI-II is a 21-question self-report survey that assesses the presence or absence of depressive 
symptoms. The sum of the scores ranges from 0-63. Scores indicate one of four outcomes: 
absence of depression (0-9), mild symptoms (10-16), moderate symptoms (17-29), and severe 
symptoms (30+). Utilization of the BDI-II was incorporated into the study for its high validity in 
identifying likely depressed and non-depressed individuals. 
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In addition, patients completed the 15-item Quality-of-Life Enjoyment and Satisfaction 
Questionnaire.30 This instrument assessed quality of life by exploring the patients’ sense of 
fulfillment and contentment with their daily experiences, overall well being, and life satisfaction.  
Visual Analogue Scales (VAS) examined patient and caregiver moods and attitudes. The 
VAS incorporated questions with scales ranging from 1-10 with “1” being the least intensity and 
“10” being the greatest intensity. When necessary, these visual scales were held by the 
interviewer for the patient to read. Patients than rated each of the questions through head 
nodding, eye movement and other established gestures. The VAS was incorporated into the study 
to ensure that those patients nearing death, who wanted to continue to contribute to the Living 
with ALS study, would be able to participate with the least amount of effort and required 
communication. The patient VAS included questions regarding degree of pain, energy, suffering, 
depression, anger, optimism, weariness, control over ALS, desire to live, and interest in 
hastening death.  
Of note, throughout the interview, research team members ensured that those patients 
with communication disabilities were able to complete survey tools through augmentative 
communication devices, eye movements, and/or other established gestures. 
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5.0  ANALYSIS OF SECONDARY DATA  
5.1.1 Determining Medication Categories and Domains 
Medication information was collected from caregivers at the first interview and at each 
subsequent interview. In order to analyze medication data for this thesis, all reported medications 
were categorized by drug purposes, which included:  
• treatment of ALS     •   anxiety 
• pain      •   agitation 
• muscle cramping & spasticity   •   depression 
• pulmonary dysfunction   •   other mood disorder 
• sialorrhea      •   cardiovascular disease 
• bowel irregularities    •   diabetes 
• sleep disorders             •   gastroesophageal reflux disease (GERD) 
• oral mouth care    •   arthritis 
• nausea      •   seizures 
• allergies     •   infection (antibiotics & steroids) 
• osteoporosis     •   hypothyroidism 
• gout      •   genitourinary disorders 
• other      •   unknown   
 
These 26 drug categories were than further collapsed into four medication domains. The domains 
consisted of:  (1) ALS treatment medication; (2) palliative medications; (3) mood medications, 
and (4) other medications. Table 2 contains a summary of medication domains and their 
subcategories. ALS treatment medications consisted of medications specifically designed to slow 
the progression of the disease and included riluzole, high-dose vitamins, gabapentin, 
antioxidants, creatine, and clinical trial medications.  
 22 
Table 2: Medication domains and their subcategories  
ALS 
Treatment Palliative Mood Other 
ALS treatment pain anxiety cardiovascular disease 
  muscle cramping agitation diabetes 
  & spasticity depression GERD  
  pulmonary dysfunction other mood disorders arthritis 
  bowel irregularities   seizures 
  sleep disorders   infection 
  oral mouth care   hypothyroidism 
  nausea   allergies 
      osteoporosis 
      gout 
      genitourinary disorders 
      other 
      unknown 
 
Palliative medications were classified as pharmacological therapies aimed at treating 
common symptoms of ALS such as pain, sialorrhea, respiratory insufficiency, constipation, 
muscle spasms, cramping, and insomnia. Medications in this category included morphine, 
glycopyrrolate, baclofen, and scopolamine. 
The practice parameters set forth by the AAN recommend the use of amitriptyline to treat 
both sialorrhea and emotional lability.26 As such, although amitriptyline is both an antidepressant 
and anxiolytic, it was included in the palliative domain for its use in controlling direct symptoms 
of ALS.  Gastroesophageal reflux disease (GERD), a less common indirect symptom, may occur 
in patients with ALS due to diaphragmatic weakness involving the lower esophageal sphincter.31  
Unlike proton pump inhibitors whose mechanism of action is to decrease acid production, 
Metoclopramide acts by increasing muscle tone of the lower esophagus sphincter. Due to its 
mechanism of action, dual uses for GERD and nausea, and frequent use for those patients who 
have percutaneous endoscopic gastrostomy (PEG) tubes, metoclopramide was added to the 
palliative domain. Proton pump inhibitors used to treat GERD were added to the other domain, 
as ALS does not cause an increase in acid production. 
 23 
Those medications aimed at treating depression, anxiety, and agitation were included in 
the mood domain. Medications included alprazolam, buspirone, bupropion, paroxetine, and 
sertraline. Included in the other domain were medications to treat chronic conditions and co-
morbidities. Medications to treat cardiovascular disease, diabetes, osteoporosis, hypothyroidism, 
gout, chronic gastrointestinal and genitourinary issues, and other unknown medications were 
included as subcategories in this domain. Medications included atrovastatin, atenolol, quinapril, 
levothyroxine, warfarin, metformin, insulin, and tamsulosin. Additionally, the other domain 
included a subcategory of “other unknown;” these medications were unidentifiably misspelled by 
the either the caregiver or interviewer.  
Caregivers in the Living with ALS study did not describe specific medication doses or 
why patients were taking particular medications. As a result, those medications that could be 
used for multiple purposes were categorized by best clinical judgment based on the available 
standards of care for ALS patients and review of patient interview data.  The medications were 
categorized by myself (a Registered Nurse) and then reviewed by the principal investigator and a 
neurologist. In one particular instance, HIV medications were moved to the ALS treatment 
domain as suggested by the principal investigator. The PI reported that the patient taking these 
medications did not have HIV but rather was trialing the medications for the purpose of treating 
ALS.  See Appendix A for a complete list of medications and their subcategories.  
5.1.2 Statistical Methods 
The percentage of patients in each medication domain was defined as all patients who took at 
least one drug in a particular domain.  
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The correlation between the medication domains and age, household income, educational 
attainment, Medicaid status, and hospice were investigated for significance using the Chi-square 
test. 
The correlation between medication domains and patient answers on the Visual Analogue 
Scale, the Beck Depression Inventory–Revised, and the Quality of Life Enjoyment and 
Satisfaction Questionnaire was investigated for significance using the Independent Samples T-
test and Levene’s test. The Independent Samples T-test and Levene’s test were used to compare 
the mean scores of patient answers to the QOL indicators and their use or non-use of medications 
in each of the four medication domains. 
To investigate the changes in medication across the last six months of life, the 
percentages of patients taking any medications in each of the four medication domains at their 
first interview was compared to the percentage of patients taking any medications in that domain 
at their last interview. The Wilcoxon Signed Ranks test was used to test for significance. 
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6.0  RESULTS 
6.1.1 Patient Sociodemographics 
A total of 78 patients and their caregivers were interviewed for this study. The gender split 
among patients was 60% male 40% female. Fifty-five percent of patients had an educational 
attainment of some college or greater. Fifty-three percent of household incomes were greater 
than $60,000. Sixteen percent of patients were receiving Medicaid and 36% were on hospice. 
See Table 3 for a list of demographics.  
      Table 3: Patient  sociodemographics 
Patient Demographics n (%) 
Age   
  <62 years old 38 (49) 
  >=62 years old 40 (51) 
Gender   
  Male 47 (60)  
  Female 31 (40)  
Education   
  No College 35 (45) 
  >= Some College 43 (55) 
Household Income   
  <60,000 36 (47) 
  >60,000 40 (53) 
Medicaid Recipient   
  Yes 12 (16) 
  No 65 (84) 
Hospice Recipient   
  Yes 27 (36) 
  No 48 (64) 
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6.1.2 Baseline Medication Use 
At the first interview 32% of patients were on an ALS treatment medication, 47% were on a 
palliative medication, 33% were on a mood medication and 31% were on an other medication. 
One third of patients were on zero medications and only 6% were taking medications from all 
four domains. Table 4 summarizes the percentage of patients in each of the four medication 
domains. 
 Table 4: Percentage of patients in each of the four medication domains 
Medication Domain 
Patients –  
n (%) 
ALS Treatment  25 (32) 
Palliative/Symptom Management 37 (47) 
Mood 26 (33) 
Other 31 (40) 
 
6.1.3 Relationship Between Sociodemographic Status and Medication Domains 
The age of the patient was found to have no significant correlation to whether or not he/she was 
taking an ALS Treatment medication, palliative medication, mood medication or other 
medication. Increased educational attainment was correlated with taking significantly fewer 
palliative medications (p= 0.001) but no correlation existed between educational attainment and 
ALS treatment medications, mood medications or other medications. Those patients with 
household incomes of greater that $61,000, which accounted for 55% of patients enrolled, were 
also less likely to be taking a palliative medication (p=0.003) but again, no correlation existed 
between income and the remaining three medication domains.  
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Those patients who received Medicaid were significantly less likely to be on a drug in the 
other medication domain (p=0.014). Patients who utilized hospice services were no more likely 
to be on ALS treatment medications, palliative medications, mood medications or other 
medications than those patients not receiving hospice care. The correlation between patient 
demographics and medication domains are summarized in Table 5.  
Table 5: Proportion of Patients with prescribed medications by sociodemographic status 
 
6.1.4 Relationship Between Quality of Life and Medication Domains 
When examining the correlation between medication domains and quality of life indicators no 
significant relationships emerged. Quality-of-life (QOL) indicators included the visual analogue 
scale (VAS), the Beck Depression Inventory-Revised (BDI-II), and the Quality-of-Life 
Enjoyment and Satisfaction Questionnaire. The QOL questions used from the VAS included:  
• What degree of pain you are feeling today? 
• How much are you suffering today? 
• How depressed are you today? 
• Are you interested in hastening your death? 
• How weary are you from ALS? 
• How much do you want to live? 
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 Across all four medication domains, VAS scores of pain, suffering, depression, desire to hasten 
death, weariness and wish to live were not significantly impacted by the use or non-use of any of 
the medications.  
Similarly, the total BDI-II score was not associated with the use of medications in each of 
the four domains. The mean total BDI-II score of patients taking a medication in each of the four 
domains did not differ significantly from the mean score of those patients not taking medication. 
Moreover, the Quality-of-Life Enjoyment and Satisfaction Questionnaire mean scores did 
not reveal any significant correlation between medication use and improved quality of life. The 
specific QOL indicator question used from the Quality-of-Life Enjoyment and Satisfaction 
Questionnaire was the following: “How would you rate your overall life satisfaction and 
contentment during the past week?” Again, as with all previous QOL indicators, patients’ mean 
scores did not differ significantly based on use or non-use of medications in each of the four 
domains. 
6.1.5 Medication Trends 
Finally, medication changes were investigated. Medications at first and lat interviews were 
compared. On average, patients’ last interviews were conducted within a month of their death. 
Previous research has shown that those ALS patients who opt for tracheostomy and long-term 
mechanical ventilation (LTMV) differ substantially from those ALS patients who do not choose 
LTMV in that LTMV patients report increased optimism and an increased desire to live.23,32  As 
such, those patients meeting a study endpoint of tracheostomy and death were analyzed 
separately. Twelve out of seventy-eight patients opted for tracheostomy. Non-tracheostomy 
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patients exhibited highly significant declines in the number of medications taken across all four 
medication domains. Tracheostomy patients had no significant changes in medications, and but 
rather remained on medications or increased medications up to the last assessment before 
tracheostomy. Table 6 summarizes the medication changes for both non-tracheostomy and 
tracheostomy patients. 
Table 6: Medication Trends–A comparison of domains at first and last interview 
Non-Tracheostomy Patients ALS Meds Pall. Meds Mood Meds Other Meds 
First Visit 36% 54% 34% 43% 
Last Visit 5% 9% 7% 5% 
Wilcoxon Signed Ranks .000 .000 .002 .000 
     
Tracheostomy Patients ALS Meds Pall. Meds Mood Meds Other Meds 
First Visit 20% 10% 50% 50% 
Last Visit 30% 20% 50% 50% 
Wilcoxon Signed Ranks ns   ns ns  ns  
(ns = not significant)  
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7.0  DISCUSSION 
7.1.1 Sociodemographics and Relationship to Medication Domains 
It was hypothesized that patients with higher incomes would be on a greater number of 
medications, due to their financial means to access such drugs. Those patients with increased 
incomes and increased educational attainment however, were prescribed significantly fewer 
palliative medications. These findings are similar to that of a study conducted in Denmark that 
investigated prescription and non-prescription drug use based on sociodemographic indicators.33 
The study found that as income decreases, prescription drug use increases even when health 
status was controlled for. The authors of the study suggested that those with lower incomes, 
because they have access to free or reduced cost services, consult physicians more frequently and 
are provided with more medications whereas those with higher incomes, who do not have access 
to free services, deal with health problems independently. 
For the patients in the Living with ALS study, higher socioeconomic status may have 
made patients ineligible for a number of financial assistance programs yet their incomes may 
have been too little to adequately afford medications. Moreover, those with increased educational 
attainment may have an increased awareness of effectiveness of palliative medications and 
choose not to take a number of the palliative medications due to the lack of clinical evidence 
indicating efficacy or a lack of personal benefit.  
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The health disparities that exist for our nation’s poor were evident in this cohort of ALS 
patients. Those on Medicaid were on significantly fewer other medications indicating that 
although they were on medications to treat and manage their ALS, they were on very few if any 
other medications to treat chronic conditions like diabetes or cardiovascular disease. 
Surprisingly, hospice patients were not prescribed any more palliative or mood 
medications than those patients not on hospice. Having hospice services increases the number of 
clinical assessments by nurses and clinicians in the home, which I believed would result in an 
increase in medications prescribed. However, hospice and non-hospice patients were on similar 
numbers of medications, indicating that hospice patients did not have an advantage for obtaining 
medications. 
Although results of this analysis indicate that those patients on hospice have no greater 
advantage to obtaining medications, a number of influencing factors must be considered. Patients 
who are referred to hospice too late may not have significant changes in their medication 
regimens, making them appear similar to their non-hospice counterparts.  Moreover, as the 
literature has demonstrated, no evidence-based studies have confirmed best practice standards for 
the terminal ALS patient. Without concrete guidelines, the progressive and terminal phases of 
the disease may not differ significantly in their medication regimens.  
To better assess the influence of hospice on access to medications, further research and 
policy changes are needed. First and foremost, hospice guidelines must be revised to accurately 
reflect the terminal stage of ALS before the effects of hospice can be determined. For this to 
happen, public health officials must work together with clinicians, patients, families, and other 
ALS patient advocacy groups to change Medicare and private health insurance criteria for end-
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of-life care for hospice ALS patients. Additionally, further research is needed to determine 
effective treatment regimens for terminal ALS patients. 
7.1.2 Relationship of QOL Indicators and Medication Domains 
According to the World Health Organization:  
Palliative care is an approach that improves the quality of life of patients and their 
families facing the problems associated with life-threatening illness, through the 
prevention and relief of suffering by means of early identification and impeccable 
assessment and treatment of pain and other problems, physical, psychosocial and 
spiritual. 34 (emphasis mine) 
 
Disappointingly, the use of medications in any of the four medications domains was not 
significantly related to the quality-of-life indicators used in this study. A plausible explanation 
could be attributed to the fact that the medications, especially those in the palliative and mood 
domains, did not provide effective symptom relief. At present, the vast majority of drugs 
available are those intended to treat symptoms and ultimately increase the quality-of-life of the 
patient. However, it appears that they fall far short of delivering improved quality-of-life. Many 
of the medications prescribed to treat the symptoms of ALS have significant side effects and 
many have few personal benefits, both of which certainly contribute to patient non-adherence to 
recommended treatment regimens. Creatine, antioxidants, and gabapentin, all medications 
frequently taken by ALS patients, have shown no clinical evidence of increasing survival or 
slowing the progression of the disease.35-37 Furthermore Riluzole, the only FDA approved 
medication for the treatment of ALS, has been found to extend life by only two months. An 
additional two months of life, especially when self-dignity and quality-of-life will almost 
certainly be greatly compromised, is hardly comforting to patients and their families.  
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 The utmost priority of ALS research is finding and developing a cure. Unfortunately this 
breakthrough has yet to occur. However, as researchers diligently investigate causes and cures, 
we must also investigate and develop new symptom management medications that have fewer 
side effects and more patient benefits.  In addition we must find and provide other interventions 
to assist ALS patients and families successful maintain quality of life. Pharmacological 
interventions used by patients in the Living with ALS study had no effect on the patient’s quality 
of life and many of the drugs were discontinued as death approached. As we attempt to improve 
our pharmacological interventions, non-pharmacological interventions should be provided and 
made accessible. The AAN indicated that the pain experienced by ALS patients during the later 
stages of the disease was most likely due to immobility. The use of physical therapy, massage, 
and acupuncture could potentially greatly reduce discomfort experienced by ALS patients. More 
research on the effectiveness of these alternative treatments could help to influence clinicians to 
prescribe these interventions more readily. However, very few (if any) insurance companies pay 
for these non-pharmacological interventions, adding to the cost of care for patients and their 
families that has already been estimated at thousands to hundreds of thousands of dollars each 
year.38 By actively pursuing policy changes and educating third-party payers of the value of 
these non-pharmacological interventions, public health professional can advocate for improved 
care of the dying.  
7.1.3 Medication Trends 
Non-tracheostomy and tracheostomy patients differed considerably in medication trends from 
first to last interview. Only 10% of eventual tracheostomy patients were on a palliative 
medication at the first visit, as compared to the rest of the cohort, in which 54% of patients were 
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on a palliative medication at first visit. Another interesting difference was in their use of ALS 
treatment medications. From first to last interview, tracheostomy patients, although not 
statistically significant, increased their use of ALS treatment medications from 20% to 30% 
whereas non-tracheostomy patients decreased their use of ALS treatment medications from 36% 
to 5% (p=0.000). These striking differences could be attributed to the tracheostomy patients’ 
desire to live and extend life. Patients undergo tracheostomies to extend life; hence it is no 
surprise that they are taking fewer palliative medications and more ALS treatment. 
Across all four medication domains, non-tracheostomy patients stopped taking 
medications as they approached their last month of life. It was hypothesized that palliative and 
mood medications would increase as ALS patients approached death. However, the analysis for 
this thesis revealed that ALS patients significantly decreased their use of medications in both of 
these domains. A number of plausible explanations could account for this significant decline in 
the number of medications taken. First and foremost, as ALS progresses, swallowing becomes 
increasingly difficult, making it correspondingly difficult to take oral medications. Secondly, 
although a number of alternative routes could be prescribed, patients may opt to forego any 
medications due to lack of personal benefit. As symptoms become increasing more severe, 
medications previously used may no longer be effective, therefore patients stop taking 
medications.  Finally, physicians may not be adequately prescribing medications to meet the 
needs of ALS patients who are approaching the actively dying stage of the disease; consequently 
there was no increase in the palliative or mood medications prescribed.  
The lack of quality-of-life, increased difficulty swallowing, and lack of evidenced based 
standards to guide physicians in the care of terminal ALS patients most likely contribute to the 
significant decline in medications taken from first interview to last interview. As has already 
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been discussed, improved symptom management medications could greatly affect the medication 
usage of patients. Additionally more research is needed to investigate and determine best practice 
standards for the terminal ALS patient. Finally, physician-patient communication must be open 
and honest. Physicians should provide accurate information about the expected benefits and side 
effects of medications to help patients make informed medication decisions. 
As hypothesized, the number of ALS treatment and other medications decreased from 
first interview to last interview. Interestingly, 5% of patients were still taking a medication in the 
domain other. It could be argued that medications to treat chronic conditions such as 
hyperlipidemia, osteoporosis and even diabetes are unnecessary in the terminal phase of any 
disease. Additionally, no drug is without side effects, and these should be considered especially 
if they have the potential to make the terminal phase of the disease more uncomfortable. 
Physicians and patients should openly discuss medication regimens as the patient transitions to 
the terminal phase of the disease, to ensure that the patient is taking the most effective and most 
appropriate pharmacological treatments.  
7.1.4 Limitations 
There are a number of limitations to the Living with ALS study and the results of this analysis.  
The study had a small sample size with a relatively low participation rate (63%). In addition, 
because patients were primarily from one ALS Center, they may not be representative. 
Moreover, data on why patients were taking particular medications was incomplete and why 
patients discontinued medications was not within the scope of this study. Because of a number of 
these limitations, medications were classified into domains, based on best clinical judgment. 
Findings of this thesis should be considered tentative rather than established. 
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8.0  CONCLUSIONS 
The results of this secondary analysis clearly demonstrate that terminal ALS patients stop taking 
medications. A number of factors could influence this decline and include inability to swallow 
medications, lack of improved quality of life, and lack of effective symptom management. To 
better understand this decline in medication usage, more research is needed, particularly 
investigating patient motivations for compliance with medication regimes, such as side effects, 
lack of personal benefit, and barriers to taking or obtaining medications. Neither the guidelines 
nor the research needs set forth by the AAN or the ALS Peer Workgroup address how patient 
choice influences compliance with medication recommendations. To better meet the needs of 
ALS patients, realistic benefits and side effects of medications should be discussed with patients 
to assist them in making decisions about medication use. Physicians should continue to offer 
patients whatever pharmacological interventions are available, but it must be considered that 
patient choice has significant ramifications for adherence. 
 In addition, continued research is needed to investigate and develop improved symptom 
management medications. Furthermore, additional research specifically investigating ALS 
patients in the terminal phase of the disease is needed to provide evidenced-based standards of 
care. 
 As pharmacological research continues to find ways to treat ALS and ultimately find a 
cure, we must also provide additional non-pharmacological interventions to improve quality of 
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life and quality of death. By investigating the effectiveness of non-pharmacological 
interventions, improved practice could be provided to the dying. Terminal ALS patients are a 
vulnerable population that require advocacy on the part of public health officials. Through 
actively pursing policy changes, hospice criteria could be altered, and improved healthcare 
reimbursement systems could assist terminal ALS patients in accessing medications and services. 
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 APPENDIX: LIVING WITH ALS STUDY: PATIENT MEDICATIONS LISTED BY 
SUBCATAGORIES AND DOMAINS 
Items written in red are the direct misspellings from the data source. 
ALSTX ALSPALL MOOD OTHER 
PAIN 
 
ANXIETY/ 
AGITATION 
 
CARDIOVASCULAR 
 
 
Rilutek 
Rilutec 
Rilytek 
Rilutex Roxanol  
(Morphine, 
Morphine Sulfate) 
Roxenol,  
Roxarol,  
Roxinol,  
Roxamol 
Roenol 
MSO4 
Ativan 
(Lorazepam) 
Lorazrpran 
Atavan 
Adavan 
Lorazapam 
Lorazepan 
Adavent 
Avodant 
Prinzide 
Privizide 
 
 
Creatine Duragesic 
(Fentanyl Patch) 
Duragenic Patch 
Fentinol 
Alprazolam 
(Xanax) 
Alprazolane 
Alprolazam 
Alprazolane 
Potassium 
Sanofi, 
Sandofi 
“Clinical 
Trial” 
Oxycodone 
(Roxicet) 
 
 
Buspirone 
(Buspar) 
Busporin 
Enalapril 
Enslapril 
Co-Q10 
Co-Enzyme 
Q10 
Co-Qio 
Darvon (Darvocet) Clonidine 
Klonopin 
 
Atenolol 
Atendol 
Indinavir 
(Cirxivan) 
Indivor 
Crixivar 
Ibuprofen 
Ibuprophine 
Stelazine 
(Schizophrenia 
or unresponsive 
anxiety) “Side 
Accupril 
Acupril 
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effects of 
coughing”? 
Viracept 
Virocept 
Tylenol #3 Chlorpromazine 
(CPZ): 
Schizophrenia; 
hiccups, nausea, 
anticholinergic 
Cardura 
Cadua 
Cadvra 
Cyclophilin 
Receptor 
Antagonist 
HIV co Claiml 
Aleve (Naproxen) Zyprexa Toprol 
Toperal 
 
Minocycline Tylenol Haldol Cozaar 
MUSCLE 
CRAMPING/ 
SPASTICITY 
 
 
Baclofen 
Baclophen 
Blaclofen 
Diazepam 
(Valium) 
Avapro 
DEPRESSION  Soma 
Wellbutrin 
(Bupropion) 
 
Lipitor 
 
 Zanaflex 
(Tizanidine) 
Tizandine 
Tizaridne 
Zana Flex 
Celexa Coumadin 
 Quinine Sulfate 
(Used for leg 
cramps has some 
components of 
Skeletal muscle 
relaxants) 
Paxil Norvasc 
PULMONARY 
DYSFUNCTION 
 
 
Hycodan  
Hycodian 
Prozac 
Prosac 
Zocor 
 
 Guaifenex 
(Humibid, 
Guaifenesin-LA)  
Zoloft Pletal 
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Humabid 
Guaifensin- LA 
 Atrovent 
(Ipratropium 
Bromide) 
Doxepin 
(Sinequan) 
Digoxin  
(Lanoxin) 
 Albuterol Serzone Lopressor 
 DuoNeb Effexor Tiazac 
Tiazar 
 Pulmozyme 
(Pulmozine) 
Fluoxetine Lasix 
Lasex 
OTHER 
 
 Mucomyst 
(Acetylcysteine) 
Anafranil 
Vasotec 
Ritalin  Saline Solution 
 
Triamterene 
SIALORRHEA 
 
ARTHRITIS 
 
 
Scopolamine 
(Transderm Scope) 
Scopolanin 
Scopolaine 
Scopolame 
 
Vioxx 
Viox 
 Sal-Tropine 
Saltropine 
 Celebrex 
Celbrex 
DIABETES  Secretion  
Glyburide 
 Elavil 
(Amitriptyline) 
Amitryphytine 
 Insulin 
 Robinul 
Robinvl 
Robinole 
Robinmul 
Robinol 
Robinal 
 Metformin 
Mefformine 
BOWEL  
IRREGULARITI
ES  
 
Cephulac 
(Lactolose)  
 Glucotrol (Glipizide) 
 
 Stool Softner  Humalin 
 Senna 
Semma 
 Glucophage 
Glucaphage 
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Glucophase 
GERD 
 
 Docusate Sodium 
(Colace) 
Ducuate Sodium 
 
Prevacid 
Prevasid 
Previcid 
Prevacia 
 Ducolax  Protonix 
SLEEP 
DISORDER 
 
Restoril 
 
 Pepcid 
GENITOURINARY 
DISORDERS  
 
 Ambien  
Ditropan XL 
 Trazadone  Flomax 
SEIZURES  ORAL MOUTH 
CARE 
 
 
Oral Mouth Gel 
 
Dilantin 
GERD/NAUSEA  
Metoclopra
mide 
(Reglan) 
 “Medication for seizures” 
 
   ALLERGIES 
 
   Allegra 
   Nasonex 
Nasenix 
   INFECTION 
   Predisone* long term 
steroid use 
   Vibramycin* 
(Doxycycline) 
Vibromicin 
Vibromycin 
   Cipro* 
   “AntiBiotic” 
OSTEOPOROSIS    
Evista 
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HYPOTHYROIDISM    
Synthroid 
GOUT    
Allopurenol 
 
OTHER    
Benadryl 
   Dexatrim 
   Marijuana 
   Neurontin (non-diabetic 
patient) 
   Chinese Herbs 
   Mepron used for treatment 
of PCP (per patient tx of 
Lyme disease) 
 
   Cephlin (maybe ceftin?) 
 (for tx of Lyme 
Disease per patient) 
   OTHER/ 
UNKNOWN 
   Riloter 
   Vceferin IV* (antibx per 
patient) 
   Serna 
   Selerium 
   Suppositories 
   Inviveol 
   Compro 
   Amsxaulll 
   Preipro 
   tep 
   Supplements 
   Bodofin 
   Rosepherme 
   Supplementary 
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